Incidence and Risk Factors for Pruritus in Patients with Nondialysis CKD.

Clin J Am Soc Nephrol

Division of Nephrology, Department of Medicine, Houston Methodist Hospital, Houston, Texas.

Published: February 2023

AI Article Synopsis

  • Pruritus is a common symptom in patients with chronic kidney disease (CKD) not on dialysis, with 34% developing moderate-to-severe itching over a 6-year follow-up period.
  • Factors such as advanced CKD, older age, high body mass index, diabetes, smoking, and depressive symptoms increase the risk of developing this condition, while low serum calcium levels may lower the risk.
  • The study underscores the importance of monitoring CKD patients for pruritus, as it significantly impacts their quality of life.

Article Abstract

Background: Pruritus is a common symptom experienced by patients with nondialysis CKD, but risk factors for incident pruritus in this patient population have not been evaluated.

Methods: We identified 1951 participants with CKD in the Chronic Renal Insufficiency Cohort Study without pruritus at the baseline assessment. Pruritus was assessed by the Kidney Disease Quality of Life-36 (KDQOL-36) instrument, and moderate-to-severe pruritus was defined as a response of 3 or higher on a Likert scale of 1-5. We used time-updated multivariable joint models to evaluate the association of patient clinical characteristics, eGFR, and laboratory parameters with incident pruritus.

Results: Over a median follow-up of 6 years, 660 (34%) participants developed incident moderate-to-severe pruritus, with a higher incidence rate observed among participants with more advanced CKD. In multivariable models, the hazard ratio (95% confidence interval [CI]) for pruritus associated with a 10 ml/min per 1.73 m 2 lower eGFR was 1.16 (95% CI, 1.10 to 1.23). Older age (≥65 years), higher body mass index, diabetes, current smoking, opioid use, depressive symptoms, and serum parathyroid hormone were also associated with a higher risk of incident pruritus, whereas low serum calcium (<9 mg/dl) was associated with a lower risk (all P <0.05). Serum phosphate was not associated with incident pruritus in the primary analysis.

Conclusions: A substantial proportion of patients with nondialysis CKD develop moderate-to-severe pruritus. Although lower eGFR is associated with the risk of pruritus, other comorbidities, particularly depressive symptoms, were potential risk factors.

Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2023_02_08_CJN09480822.mp3.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103216PMC
http://dx.doi.org/10.2215/CJN.09480822DOI Listing

Publication Analysis

Top Keywords

pruritus
9
risk factors
8
patients nondialysis
8
nondialysis ckd
8
incident pruritus
8
moderate-to-severe pruritus
8
incidence risk
4
factors pruritus
4
pruritus patients
4
ckd
4

Similar Publications

Scratching more than an itch.

Science

January 2025

Divison of Allergy and Immunology, John T. Milliken Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.

Enhanced antibacterial skin inflammation is an adaptation of the itch-scratch cycle.

View Article and Find Full Text PDF

Itch is a dominant symptom in dermatitis, and scratching promotes cutaneous inflammation, thereby worsening disease. However, the mechanisms through which scratching exacerbates inflammation and whether scratching provides benefit to the host are largely unknown. We found that scratching was required for skin inflammation in mouse models dependent on FcεRI-mediated mast cell activation.

View Article and Find Full Text PDF

Background: Long-term (2-year) effectiveness of upadacitinib for atopic dermatitis (AD) is unknown in real-world practice.

Objective: To evaluate 96-week real-world effectiveness of upadacitinib in Japanese patients with moderate-to-severe AD, stratified by the presence or absence of prior systemic therapies.

Methods: This prospective study included 327 Japanese patients treated with upadacitinib 15 mg (n = 248) or 30 mg (n = 79).

View Article and Find Full Text PDF

Background: Skin symptom burden, varying with patient populations, may not be readily observed by clinicians, resulting in incomplete appreciation of total skin disease burden.

Objective: The purpose of this study was to define patient itch burdens and associated health-related QOL affecting different patient demographics and to identify potential population health disparities.

Methods: This is a cross-sectional, secondary data analysis of data captured using an automated routine electronic previsit survey completed by patients who visited Emory Healthcare Dermatology clinic between March 2021 and October 2022 (6532 patient visits).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!